Company / R&D per Share
CG Oncology, Inc. R&D per Share History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.51
FY2025
5-year range
$1.31 / $10.56
FY2023-FY2025
Trend
+14.9%
vs FY2024
Sector context
#122 of 208
Health Care
What the data says
At $1.51, CG Oncology, Inc.'s r&d per share ranks #122 of 208 in the Health Care sector. Declined from $10.56 to $1.51 over the past 2 years.
Based on SEC 10-K filings.
1.51 in FY2025.
Declined from $10.56 to $1.51 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#122 of 208 in Health CareTop 59% of 208This company $1.51 Sector average $28.77
▼
-94.8% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 14.9% year-over-year.
- Ranks #122 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 8.02 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.51 | +14.9% |
| FY2024 | $1.31 | -87.6% |
| FY2023 | $10.56 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026